Post-transplantation Cyclophosphamide for Haploidentical Transplant From Maternal or Collateral Donors

Phase 4

Completed

• Conditions: Hematopoietic Stem Cell Transplantation
• Interventions: Drug: post-transplantation cyclophosphamide

• Registration Number: NCT02412423
• Lead Sponsor: Peking University People's Hospital

Brief Summary

In "beijing model" for haploidentical transplant, the rate of acute graft-versus-host disease (GVHD) from maternal or collateral donors was significantly higher than that from other kins. To reduce the GVHD incidence from maternal or collateral donors, post-transplantation cyclophosphamide is planned to be added into the protocol in "beijing model".

Detailed Description

Not available

Study Timeline

• Study Start: 2015-03
• Study First Submitted: 2015-04-05
• Study First Submitted QC: 2015-04-08
• Study First Posted: 2015-04-09
• Primary Completion: 2016-08
• Study Completion: 2017-03
• Status Verified: 2020-09
• Last Update Submitted: 2020-09-15
• Last Update Posted: 2020-09-17

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 30

Inclusion Criteria

• haploidentical patients from maternal or collateral donors

Exclusion Criteria

• uncontrolled infection before transplant

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
treatment group	post-transplantation cyclophosphamide	post-transplantation cyclophosphamide

Primary Outcome Measures

Name	Time	Method
rate of acute GVHD	participants will be followed for an expected average of 365 days

Secondary Outcome Measures

Name	Time	Method
rate of non-relapse mortality	participants will be followed for an expected average of 365 days
rate of relapse	participants will be followed for an expected average of 365 days
probability of survival	participants will be followed for an expected average of 365 days

Trial Locations

Locations (1)

Peking University People's Hospital; 🇨🇳 Beijing, China